Intas Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Intas Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 75 Products, $372.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Intas Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 75 Products, $372.3M Trade | TransData Nexus

Intas Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $372.3M Total Trade · DGFT Verified

Intas Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $372.3M across 75 products in 19 therapeutic categories. Based on 18,876 verified export shipments from Indian Customs (DGFT) records, Intas Pharmaceuticals Limited is the #1 Indian exporter in 17 products including Mycophenolate, Atorvastatin, Irinotecan. Top exports include Ras ($39.1M), Mycophenolate ($23.4M), Tacrolimus ($22.5M).

Intas Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Intas Pharmaceuticals Limited pharmaceutical export portfolio — 75 products across 19 therapeutic categories. Source: Indian Customs (DGFT).

Who is Intas Pharmaceuticals Limited? — Company Overview & Market Position

Intas Pharmaceuticals Limited, established in 1985, is a prominent Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. The company specializes in the development, manufacturing, and marketing of generic therapeutic drugs, operating across more than 85 countries. Intas is privately held, with the Chudgar family holding an 83.85% stake, Temasek Holdings owning 10.13%, and ChrysCapital possessing 6.02%. The company's Corporate Identification Number (CIN) is U24231GJ1985PLC007866. As of 2025, Intas employs over 24,000 professionals globally. The company's official website is www.intaspharma.com.

What Does Intas Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ras$39.1M 2Mycophenolate$23.4M

Product Portfolio — Top 30 by Export Value

Intas Pharmaceuticals Limited exports 75 pharmaceutical products across 19 therapeutic categories. Market leader (#1 exporter) in 17 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ras	Ayurvedic & Herbal Products	$39.1M	782	11.9%	2
2	Mycophenolate	Immunosuppressants	$23.4M	468	6.8%	1
3	Tacrolimus	Immunosuppressants	$22.5M	588	11.2%	4
4	Apixaban	Cardiovascular	$18.7M	436	10.4%	3
5	Ezetimibe	Lipid & Metabolism	$16.6M	333	3.2%	3
6	Iron	Vitamins & Supplements	$16.5M	1,319	3.4%	4
7	Atorvastatin	Cardiovascular	$16.4M	328	1.5%	1
8	Telmisartan	Cardiovascular	$15.5M	461	0.1%	3
9	Irinotecan	Oncology	$15.1M	1,120	35.8%	1
10	Levothyroxine	Diabetes & Endocrine	$15.0M	598	18.9%	2
11	Spironolactone	Diuretics	$12.2M	1,026	6.2%	4
12	Anastrozole	Advanced Oncology	$10.4M	209	9.4%	1
13	Letrozole	Advanced Oncology	$7.2M	512	21.6%	2
14	Capecitabine	Advanced Oncology	$6.4M	227	5.7%	5
15	Metoprolol	Cardiovascular	$6.2M	347	0.8%	11
16	Pravastatin	Cardiovascular	$6.1M	122	19.6%	1
17	Paclitaxel	Oncology	$5.9M	405	7.1%	3
18	Carboplatin	Oncology	$5.8M	209	6.8%	3
19	Clopidogrel	Cardiovascular	$5.3M	301	2.1%	14
20	Cytarabine	Advanced Oncology	$5.1M	693	47.6%	1
21	Etoposide	Oncology	$5.1M	596	44.5%	1
22	Exemestane	Advanced Oncology	$4.9M	273	31.1%	1
23	Fluoxetine	CNS & Psychiatric	$4.8M	97	2.1%	2
24	Fulvestrant	Advanced Oncology	$4.6M	167	30.3%	1
25	Citalopram	CNS & Psychiatric	$4.1M	400	1.6%	12
26	Escitalopram	CNS & Psychiatric	$4.1M	391	2.1%	11
27	Gemcitabine	Oncology	$3.8M	234	7.9%	5
28	Pioglitazone	Diabetes & Endocrine	$3.8M	502	9.1%	3
29	Montelukast	Respiratory	$3.8M	400	2.2%	8
30	Cabazitaxel	Advanced Oncology	$3.7M	111	38.4%	1

Intas Pharmaceuticals Limited exports 75 pharmaceutical products across 19 therapeutic categories with a total export value of $372.3M. The company is the #1 Indian exporter in 17 products: Mycophenolate, Atorvastatin, Irinotecan, Anastrozole, Pravastatin and 5 more. The top category is Cardiovascular (21.1% of portfolio), followed by Advanced Oncology (16.3%), reflecting a diversified portfolio where the top 5 products account for only 32.3% of total value.

Showing top 30 of 75 products. Contact us for complete data.

Intas Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Intas Pharmaceuticals operates a network of fourteen formulation manufacturing facilities, with eleven located in India and the remaining three in the United Kingdom and Mexico. These facilities are designed to produce a wide range of dosage forms, including tablets, capsules, syrups, and injections, catering to various therapeutic areas. The Ahmedabad Special Economic Zone (SEZ) facility is dedicated exclusively to serving the U.S., European, and other regulated markets. Additionally, Intas has invested in the Pharmez 2 facility in Gujarat, India, which boasts a capacity to produce over one billion solid oral doses and five million injectable units monthly.

3Key Leadership

The leadership team at Intas Pharmaceuticals is spearheaded by Managing Director Urmish Hasmukh Chudgar, who plays a pivotal role in the company's strategic direction. Other key executives include Vice Chairman and Joint Managing Director Binish Chudgar, Joint Managing Director and CEO Nimish Chudgar, and Joint Managing Director Urmish Chudgar. The board also comprises directors such as Hasmukh Chudgar, Archana Ravindrarai Dholakia, and Sanjiv Dwarkanath Kaul.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Intas Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Intas Pharmaceuticals has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's products are approved by various international regulatory bodies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Intas has also acquired assets from Teva Pharmaceuticals in the UK and Ireland, enhancing its footprint in these markets.

2Emerging Markets

Intas Pharmaceuticals has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) prequalification standards has facilitated access to these regions, enabling the supply of quality-assured medicines to underserved populations. This strategic expansion aligns with Intas's commitment to global health and access to essential medicines.

3Geographic Strategy

Intas Pharmaceuticals demonstrates a diversified geographic strategy, balancing its presence across regulated and emerging markets. While the company has a strong foothold in developed markets, its expansion into emerging regions mitigates concentration risk and opens avenues for growth. This strategic direction reflects Intas's commitment to global health and its vision of becoming a leader in the pharmaceutical industry.

Intas Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Intas Pharmaceuticals maintains FDA facility registrations and has received approvals for multiple Abbreviated New Drug Applications (ANDAs). The company's facilities have undergone inspections by the FDA, ensuring compliance with stringent quality standards. Intas's commitment to quality is further demonstrated by its adherence to Good Manufacturing Practice (GMP) guidelines, which are essential for maintaining the integrity of pharmaceutical products.

2WHO & EU GMP

Intas Pharmaceuticals has achieved WHO prequalification for several of its products, ensuring they meet international quality standards. The company's manufacturing facilities have also received EU GMP certification, reflecting compliance with European Union regulations. These certifications underscore Intas's commitment to producing high-quality medicines for global markets.

3CDSCO & Indian Regulatory

Intas Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers across India. The company has also secured export No Objection Certificates (NOCs), facilitating the export of its products to various international markets. These regulatory approvals affirm Intas's compliance with national standards and its capability to supply medicines globally.

Intas Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Intas Pharmaceuticals faces competition from other Indian pharmaceutical exporters such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla. In the therapeutic categories of cardiovascular, advanced oncology, and immunosuppressants, Intas holds significant market shares, indicating a strong competitive position. The company's focus on high-quality generic formulations and strategic acquisitions has bolstered its presence in both regulated and emerging markets.

2Key Differentiators

Intas Pharmaceuticals distinguishes itself through its extensive product portfolio, including a strong presence in cardiovascular, oncology, and immunosuppressant formulations. The company's manufacturing facilities comply with international regulatory standards, ensuring high-quality products. Strategic acquisitions, such as those of Teva's UK and Ireland assets, have enhanced its market reach and capabilities.

3Strategic Position

Intas Pharmaceuticals is strategically positioned as a leading player in the generics market, with a growing focus on biosimilars and contract development and manufacturing organization (CDMO) services. The company's investments in advanced manufacturing facilities and adherence to global regulatory standards underscore its commitment to quality and innovation. Looking ahead, Intas aims to expand its global footprint and enhance its product offerings to meet the evolving needs of the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Intas Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Intas Pharmaceuticals has a robust track record in the pharmaceutical industry, with a diverse product portfolio and a significant presence in both regulated and emerging markets. The company's manufacturing facilities are designed to deliver high-quality products within defined cost and delivery schedules. Intas's commitment to quality is demonstrated by its compliance with international regulatory standards and certifications.

2Certifications to Verify

Importers should verify the following certifications when considering Intas Pharmaceuticals as a supplier:

FDA Approval: Confirm the company's FDA facility registrations and approved ANDAs.

WHO-GMP Certification: Ensure the company holds WHO prequalification for relevant products.

EU GMP Certification: Verify that manufacturing facilities comply with EU GMP standards.

Frequently Asked Questions — Intas Pharmaceuticals Limited

How many pharmaceutical products does Intas Pharmaceuticals Limited export from India?

How many pharmaceutical products does Intas Pharmaceuticals Limited export from India? A1: Intas Pharmaceuticals Limited exports 75 pharmaceutical products from India, covering 19 therapeutic categories.

What is Intas Pharmaceuticals Limited's total pharmaceutical export value?

What is Intas Pharmaceuticals Limited's total pharmaceutical export value? A2: Intas Pharmaceuticals Limited's total pharmaceutical export value is $372.3 million USD.

Get Full Intas Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.